| Abstrakt: |
A new report from the University of Ferrara presents fresh data on chronic myeloid leukemia (CML). The study analyzed the baseline features, treatment choice, and early adverse events leading to permanent discontinuation of tyrosine kinase inhibitors (TKIs) in younger patients with CML. The research found that younger patients had higher white blood cell counts, lower hemoglobin levels, and a higher rate of spleen enlargement compared to older patients. Additionally, younger patients were more likely to receive second-generation TKIs as frontline treatment. The study also observed a lower incidence of early TKI discontinuation in younger patients, mainly due to toxic causes rather than resistance. Further evaluation is needed to complete the analysis. [Extracted from the article] |
